Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Recruiting N/A Interventional Study
Antiphospholipid Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
60 (estimated)
Sponsor
Centre Hospitalier Universitaire, Amiens · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in antiphospholipid syndrome (APS). ANXA2 can exist as a monomer or a heterotetrameric complex with S100A10 protein. The aim of this study was to evaluate the cell membrane expression …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * APS patients who fulfilled the revised criteria for APS Exclusion Criteria: * Patients less than 18 years old * Solid and hematological malignancies * Other autoimmune diseases * Cirrhosis
Contacts

Valéry Salle, MD

03 22 66 82 30

salle.valery@chu-amiens.fr

CONTACT